|
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2- based regimen.
Earlier on 3 May 2023, the company gets the receipt of import and market permission in form CT-20 from the Drugs Controller General of India for Trastuzumab deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion (Enhertu).
Astrazeneca Pharma is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company. The major therapy areas where the company operates are onocology, alimentary & metabolism, cardio vascular, renal, diabetes, respiratory and oncology.
The company's standalone net profit jumped 25% to Rs 40.71 crore on a 31.7% increase in net sales to Rs 311.07 crore in Q2 FY24 over Q2 FY23.
|